Trial reportJournal of neuro-oncology2019
Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study.
Trial report in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024.Frontiers in oncology · 2024Pooled it
- A case of carotid blowout syndrome following endoscopic endonasal surgery and proton beam therapy for chondrosarcoma: Considering the role of nasoseptal mucosal flap for minimizing bleeding.Surgical neurology international · 2026Article
- Evaluating the technical feasibility of biology-guided dose painting in proton therapy.Physics and imaging in radiation oncology · 2025Article
- Skull-Base Chondrosarcoma: A Systematic Review of the Role of Postoperative Radiotherapy.Cancers · 2024Review
- Global research development of chondrosarcoma from 2003 to 2022: a bibliometric analysis.Frontiers in pharmacology · 2024Review
- Review
- A multicenter retrospective analysis of clinical outcomes of intracranial chondrosarcoma in 26 patients.Scientific reports · 2023Article
- Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions.Cancers · 2023Review
- Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.Journal of neuro-oncology · 2023Article
- Clinical Characteristics and Prognostic Risk Factors of Parasellar Chondrosarcoma.Brain sciences · 2022Article
- Revisitation of imaging features of skull base chondrosarcoma in comparison to chordoma.Journal of neuro-oncology · 2022Article
- Impact of Type of Treatment Center and Access to Care on Mortality and Survival for Skull Base Chordoma and Chondrosarcoma.Journal of neurological surgery. Part B, Skull base · 2022Article
- Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives.Cancers · 2022Review
- Differences in the Establishment of Gut Microbiota and Metabolome Characteristics Between Balb/c and C57BL/6J Mice After Proton Irradiation.Frontiers in microbiology · 2022Article
- Activation of efficient DNA repair mechanisms after photon and proton irradiation of human chondrosarcoma cells.Scientific reports · 2021Article
- Primary Skull Base Chondrosarcomas: A Systematic Review.Cancers · 2021Review
- Article
- Effects of a combined therapy of bortezomib and ionizing radiation on chondrosarcoma three-dimensional spheroid cultures.Oncology letters · 2021Article
- Long-term outcomes of grade I/II skull base chondrosarcoma: an insight into the role of surgery and upfront radiotherapy.Journal of neuro-oncology · 2021Article
- Proton Therapy for Skull-Base Chordomas and Chondrosarcomas: Initial Results From the Beaumont Proton Therapy Center.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to evaluate the effectiveness of definitive or adjuvant external-beam proton therapy on local control and survival in patients with skull-base chondrosarcoma.
methodsWe reviewed the medical records of 43 patients with a median age of 49 years (range, 23-80 years) treated with double-scattered 3D conformal proton therapy for skull-base chondrosarcomas between January 2007 and February 2016. Proton therapy-related toxicities were scored using CTCAE v4.0.
resultsThe median radiotherapy dose was 73.8 Gy(RBE) (range, 64.5-74.4 Gy[RBE]). Thirty-six (84%) and 7 (16%) patients underwent surgical resection or biopsy alone. Tumor grade distribution included: grade 1, 19 (44%) patients; grade 2, 22 (51%); and grade 3, 2 (5%). Forty patients had gross disease at the time of radiotherapy and 7 patients were treated for locally recurrent disease following surgery. The median follow-up was 3.7 years (range, 0.7-10.1 years). There were no acute grade 3 toxicities related to RT. At 4 years following RT, actuarial rates of overall survival, cause-specific survival, local control, and RT-related grade 3 toxicity-free survival were 95%, 100%, 89%, and 95%.
conclusionHigh-dose, double-scattered 3D conformal proton therapy alone or following surgical resection for skull-base chondrosarcoma is an effective treatment with a high rate of local control with no acute grade 3 radiation-related toxicity. Further follow-up of this cohort is necessary to better characterize long-term disease control and late toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.